Abstract：Objective: To analyze the expression and clinical significance of epidermal growth factor receptor (Epidermal growth factor receptor , EGFR) gene in pleuroperitoneal fluid cells of paraffin blocks. Methods: A total of 72 pleuroperitoneal fluid cell paraffin blocks specimens which were archived in the hospital from June 2018 to June 2019 were collected. The staining situations of paraffin blocks specimens were observed by immunohistochemistry. The relative expression level of EGFR gene was detected by Real-Time PCR. The mutation of EGFR gene in pleuroperitoneal fluid cells of paraffin blocks was detected by Amplification Refractory Mutation System. The comparison situations between the detection results of EGFR gene mutation in malignant pleuroperitoneal fluid cells of paraffin blocks and the histopathological results were analyzed. Results: Immunohistochemical results showed that the EGFR gene was negative and weakly positive in benign pleuroperitoneal fluid cells of paraffin blocks, while it showed positive expression of different degrees in the malignant pleuroperitoneal fluid cells. The relative expression level of EGFR gene in malignant pleuroperitoneal fluid cells of paraffin blocks was significantly higher than that in benign paraffin blocks (P<0.05). Among the 53 malignant pleuroperitoneal fluid cells paraffin blocks, there was 1 case with EGFR gene mutation. There were deletion mutations at the 19th exon of EGFR gene, and mutation site was E746-A750 DEL. There were no mutation and SNP locus at 18th, 20th and 21th exon of EGFR gene. Taking histopathological results as the golden standard, Kappa value and detection accuracy rate of EGFR gene mutation in malignant pleuroperitoneal fluid cells of paraffin blocks were 0.658 and 98.08%, respectively. Conclusion: The high expression of EGFR gene in pleuroperitoneal fluid cells of paraffin blocks is an early warning of malignant pleuroperitoneal fluid. Mutation at E746-A750 DEL of EGFR gene 19th exon can improve the drug sensitivity of targeted therapy.
[1] 杨丽英,朱杰.细胞块切片联合免疫组化在浆膜腔积液诊断中的应用[J].标记免疫分析与临床,2019,26(1):98~101. [2] 李文,陈洁,胡伟男,等.EGFR耐药突变及其小分子抑制剂研究进展[J].中国生物工程杂志,2019,14(10):21~23. [3] 叶丹,谢长生.表皮生长因子受体酪氨酸激酶抑制剂相关皮疹的中西医治疗进展[J].肿瘤学杂志,2019,25(3):256~260. [4] Rafael R,Laurence L,Marie A,et al.Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib,erlotinib and osimertinib,the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients[J].Journal of Pharmaceutical&Biomedical Analysis,2018,158:174~183. [5] Kortekaas Kim Esmée,Philip P H M.Hydrothorax,ascites and an abdominal mass:not always signs of a malignancy-Three cases of Meigs'syndrome[J].Journal of Radiology Case Reports,2018,12(1):21~23. [6] 徐敏,何婉,李岚,等.非小细胞肺癌患者胸腔积液与外周血ctDNA中EGFR基因突变检测的对比研究[J].新医学,2018,49(5):346~349. [7] Sigismund S,Avanzato D,Lanzetti L.Emerging functions of the EGFR in cancer[J].Molecular Oncology,2018,12(1):13~20. [8] 刘冲,李涛,季盼,等.肺腺癌胸水细胞蜡块表皮生长因子受体检测的价值[J].江苏医药, 2018,15(8):895~897. [9] 陈辉,段智,韦妹艳.EGFR基因突变型和非小细胞肺癌EGFR表达水平的相关性研究[J].国际医药卫生导报,2017,23(24):3862~3865.
2020, Vol. 26 
冀公网安备13080202000677号